Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00640939
Other study ID # DCF-003
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received March 18, 2008
Last updated August 5, 2008
Start date December 2007
Est. completion date June 2008

Study information

Verified date August 2008
Source Cerimon Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary purpose of this study is to assess the effectiveness of once daily application of a diclofenac sodium patch to the skin near or over the painful area. In this study, the location being studied will be one of the following: the affected shoulder, elbow, or wrist.

The secondary purpose of this study is to assess the safety and tolerability of the diclofenac patch on the subject's skin, in the location being studied.


Description:

Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.


Recruitment information / eligibility

Status Completed
Enrollment 308
Est. completion date June 2008
Est. primary completion date April 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- 18 years to 75 years of age

- Onset of painful upper extremity tendonitis or bursitis, no more than 21 days prior to study entry

- Eligible diagnoses are rotator cuff tendonitis, bicipital tendonitis or subdeltoid/subacromial bursitis of the shoulder, medial or lateral epicondylitis of the elbow, and DeQuervain's tenosynovitis of the wrist

- Spontaneous pain with motion or resisted motion and tenderness to palpation over the involved tendon(s), bursa, or epicondyle

- Presence of pain of at least 5, with a maximum of 9, on an 11-point Numerical Rating Scale (NRS)

Exclusion Criteria:

- Aspirin, or short half-life NSAID use within 12 hours, or longer half-life NSAID use within 24 hours prior to study entry (see Appendix B: for table of NSAIDs)

- Opioid use within 3 days prior to study entry

- Topical treatment, other than local ice or heat, applied to the painful region within 3 days prior to study entry

- History of peptic ulcer disease within 1 year prior to study entry, any history of gastrointestinal bleeding, or coagulation disorder

- A history of, or evidence for underlying articular disease such as osteoarthritis, rheumatoid arthritis, gout, or pseudogout (calcium pyrophosphate deposition disease)

- Clinically significant and poorly controlled pulmonary, gastrointestinal, hepatic, renal, endocrine, or cardiovascular disease

- A history of hypersensitivity to diclofenac or diclofenac-containing products

- A history of intolerance to acetaminophen (rescue medication in this trial)

- A history of skin sensitivity to adhesives (e.g. adhesive tape)

- Pregnant or breastfeeding women and women of child-bearing potential not using effective means of contraception

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
diclofenac sodium
15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
Matching Placebo
Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily

Locations

Country Name City State
United States PPD Austin Texas

Sponsors (2)

Lead Sponsor Collaborator
Cerimon Pharmaceuticals PPD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the efficacy of diclofenac in subjects with tendonitis or bursitis of the shoulder, elbow, or wrist. 14 days No
Secondary Assess the safety and tolerability of diclofenac in subjects with tendonitis or bursitis of the shoulder, elbow, or wrist. 14 days No
See also
  Status Clinical Trial Phase
Completed NCT01330641 - Accuracy of Needle Placement Into The Subacromial Space of The Shoulder N/A